Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent


Lung cancer is the most lethal cancer, and almost 90% of lung cancer is due to cigarette smoking. Even though nicotine, one of the major ingredients of cigarette smoke and the causative agent for addiction, is not a carcinogen by itself, several investigators have shown that nicotine can induce cell proliferation and angiogenesis.

We observed that the proliferative index of nicotine is different in the lung cancer cell lines H1299 (p53-/-) and A549 (p53+/+) which indicates that the mode of up-regulation of survival signals by nicotine might be different in cells with and without p53.

Results: While low concentrations of nicotine induced activation of NF-kappaB, Akt, Bcl2, MAPKs, AP1 and IAPs in H1299, it failed to induce NF-kappaB in A549, and compared to H1299, almost 100 times higher concentration of nicotine was required to induce all other survival signals in A549. Transfection of WT-p53 and DN-p53 in H1299 and A549 respectively, reversed the mode of activation of survival signals.

Curcumin down-regulated all the survival signals induced by nicotine in both the cells, irrespective of their p53 status. The hypothesis was confirmed when lower concentrations of nicotine induced NF-kappaB in two more lung cancer cells, Hop-92 and NCI-H522 with mutant p53 status.

Silencing of p53 in A549 using siRNA made the cells susceptible to nicotine-induced NF-kappaB nuclear translocation as in A549 DN-p53 cells.

Conclusions: The present study reveals a detrimental role to nicotine especially in lung cancer patients with impaired p53 status and identifies curcumin as a potential chemopreventive.

Author: Vineshkumar PuliyappadambaVino CheriyanArun Kumar ThulasidasSmitha BavaBalachandran VinodPriya PrabhuRanji VargheseArathy BevinShalini VenugopalRuby Anto
Credits/Source: Molecular Cancer 2010, 9:220



Published on: 2010-08-20



Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo



Comments Page 0 of 0
There are currently 0 comments to display.

 


+ Add New Comment


Custom Search

Username
Password










© 2012 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk
There are currently 47101 people browsing 7thSpace